<SEC-DOCUMENT>0001437749-14-007806.txt : 20140502
<SEC-HEADER>0001437749-14-007806.hdr.sgml : 20140502
<ACCEPTANCE-DATETIME>20140502095341
ACCESSION NUMBER:		0001437749-14-007806
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140502
DATE AS OF CHANGE:		20140502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		14807214

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20140501_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>govx20140501_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; BORDER-TOP: medium none; BORDER-RIGHT: medium none">

<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA84><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA85><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA86><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA87><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 21%; HEIGHT: 2px; COLOR: #000000; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA88><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA89><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA90><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>FORM 8-K </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA91><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA92><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>CURRENT REPORT </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA93><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA94><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA95><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA96><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Date of report (Date of earliest event reported): May 1, 2014</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA97><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA98><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 21%; HEIGHT: 2px; COLOR: #000000; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA99><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA100><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>GEOVAX LABS, INC.</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA101><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Exact name of registrant as specified in Charter) </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA102><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA103><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA104><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL116  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA105><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA106><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA107><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>000-52091</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA108><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA109><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>87-0455038</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA110><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(State or other jurisdiction of</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA111><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>incorporation or organization)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA112><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA113><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Commission File No.)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA114><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA115><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(IRS Employee Identification No.)</B></FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA117><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA118><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>1900 Lake Park Drive</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA119><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Suite 380</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA120><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Smyrna, Georgia 30080</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA121><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Address of Principal Executive Offices) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA122><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA123><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(678) 384-7220</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA124><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Issuer Telephone number) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA125><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA126><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA127><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA128><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA129><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA130><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA131><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA132><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA133><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA134><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA135><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA136><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: 0px; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
</FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA137.1><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK137 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR137 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM137 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR137 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA137.2><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA138><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant&#39;s management as well as estimates and assumptions made by the registrant&#39;s management. When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative if these terms and similar expressions as they relate to the registrant or the registrant&#39;s management identify forward looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant&#39;s industry, operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA139><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="TEXT-INDENT: 0;WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL140  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="VERTICAL-ALIGN: top" width=94>
<P id=PARA178><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 2.02</FONT></B></P></TD>
<TD style="VERTICAL-ALIGN: top" width=1077>
<P id=PARA179><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Results of Operations and Financial Condition</P></FONT></B></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA141><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA142><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On May 1, 2014 we issued a press release reporting our results of operations for the quarter ended March 31, 2014. A copy of the press release is attached to this Current Report.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA143><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="TEXT-INDENT: 0;WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL144  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 94px; VERTICAL-ALIGN: top">
<P id=PARA180><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 9.01</FONT></B></P></TD>
<TD style="WIDTH: 1077px; VERTICAL-ALIGN: top">
<P id=PARA181><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Financial Statements and Exhibits</P></FONT></B></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA145><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="TEXT-INDENT: 0;WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL146  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 94px; VERTICAL-ALIGN: top">
<P id=PARA182><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Exhibit 99.1</FONT></P></TD>
<TD style="WIDTH: 1077px; VERTICAL-ALIGN: top">
<P id=PARA183><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Press Release</P></FONT></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -63pt; MARGIN: 0pt 0pt 0pt 63pt" id=PARA147><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA148><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>SIGNATURES</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA149><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA150><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA151><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA152><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dated: May 2, 2014</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA153><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL177  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA164><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA165><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GEOVAX LABS, INC.</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA166><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA167><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA168><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA169><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA170><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA171><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA172><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA173><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">By:<U>&nbsp;&nbsp;&nbsp;/s/ Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA174><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA175><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp; Mark W. Reynolds </FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA176><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp; Chief Financial Officer</FONT></P></TD></TR></TABLE></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="TEXT-ALIGN: right; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA125><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Exhibit 99.1</B></FONT></P>
<P style="TEXT-ALIGN: left; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA126><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>&nbsp;</P><IMG src="logo.jpg" width=193 height=68>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA4><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA5><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>GeoVax Reports 2014 First Quarter Financial Results</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA6><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>And Provides Corporate Update</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA7><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA8><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA9><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>ATLANTA, GA, May 1, 2014 &#8211; </B>GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2014 and provided a corporate update.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA11><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>First Quarter Developments and Highlights</U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA13><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Therapeutic HIV Vaccine &#8211; Phase 1 Trial Data. </I>In January, GeoVax announced preliminary results for a Phase 1 clinical trial (GV-TH-01) investigating the therapeutic use of GOVX-B11 in HIV-infected patients. GV-TH-01 is an open label study testing the safety and immunogenicity of the GOVX-B11 DNA/MVA vaccine in HIV-infected patients who initiated antiretroviral drug therapy (ART) within 18 months of seroconversion and had stably controlled virus for at least 6 months. Patients were vaccinated with two DNA inoculations followed by two MVA inoculations at intervals of two months. Eight weeks following the last inoculation, patients suspended drug therapy for a 12 week period. Vaccinated patients&#8217; ability to control the time and temporal height of re-emergent virus in the absence of drugs was then observed. Drug treatment was re-instituted after 12 weeks, and trial participants were observed for an additional 6 months. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA15><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Excellent safety was observed throughout the trial, with none of the 9 participants needing to reinstate antiretroviral drugs during the treatment interruption phase of the trial. GeoVax&#8217;s initial analysis of the trial data indicates that, during the vaccination phase of the trial, enhanced CD8+ T cells were elicited in 8 of 9 participants and enhanced CD4+ T cell in 5 of 9 participants. Antibody responses were boosted in 4 of 9 participants. Analyses during the treatment interruption phase suggested that individuals with the best immune responses to the vaccine had lower levels of re-emergent virus. These results and other positive observations from this study have given the Company rationale to proceed with its therapeutic vaccine clinical development program.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA16><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA17><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax expects to formally publish study results for GV-TH-01 in a scientific journal in late-2014.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA18><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA19><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Therapeutic HIV Vaccine &#8211; Planned Follow-on Trial.</I>&nbsp;&nbsp;&nbsp;&nbsp;Based on the encouraging results from GV-TH-01, GeoVax is planning the next therapeutic trial as part of the new effort to achieve a cure for HIV infection. Current plans are for a Phase 1 clinical trial investigating the treatment of HIV-positive individuals with GeoVax&#8217;s vaccine in combination with standard-of-care antiretroviral drug therapy (ART). Instead of removing patients from oral drugs as was done in GV-TH-01, the anticipated trial design will have participants continue ART to allow investigation of the vaccine&#8217;s effect on latent reservoirs of virus. Initiation of this trial is subject to financing availability, and GeoVax intends to seek NIH as well as private support.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA20><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Preventive HIV Vaccine &#8211; Planned Phase 2 Efficacy Trial</I>. Based on results from a Phase 1 trial (HVTN 094) of the adjuvanted version of GOVX-B11 being conducted by the HIV Trials Network (HVTN) with funding from the National Institutes of Health (NIH), together with additional nonhuman primate data and further analysis of the completed Phase 2a trial (HVTN 205) of GOVX-B11, GeoVax will advance GOVX-B11 to the next stage of clinical testing for a preventive HIV vaccine. </FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA22><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA23><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax is now in planning discussions with the HVTN and NIH for a Phase 2 efficacy trial of GOVX-B11, and several scenarios are being considered. In GeoVax&#8217;s recent public statements, the possible addition of a protein boost to GOVX-B11 was discussed; but recent conversations with the HVTN leads the Company to believe that this may not be required for a Phase 2 trial to proceed. Specific details of the Phase 2 efficacy trial will be clearer after further data analysis and input from the HVTN and NIH in mid-2014. GeoVax believes that GOVX-B11 is ready for a Phase 2b placebo-controlled efficacy trial. However, without independent funding for the trial, trial designs and priorities will be determined by the government and academic groups financing and leading HIV vaccine trials. </FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA127.1><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK127 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR127 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM127 ><B>MORE</B>&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR127 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA127.2><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA25><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Robert McNally, Ph.D., GeoVax&#8217;s President and Chief Executive Officer, commented, &#8220;All of us in the HIV community are excited about the significant progress toward a vaccine to prevent HIV. Even today, with the vast array of antiviral drugs available, about 50,000 individuals in the U.S. alone are annually infected with HIV. GOVX-B11 is now recognized as the lead vaccine candidate to prevent clade B HIV infection in humans. We are grateful for the continued support from the HVTN and NIH as our vaccine moves forward in the clinical trial process.&#8221;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>Financial Review</U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA29><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax reported a net loss for the three months ended March 31, 2014 of $614,918, or $0.02 per share, based on 24.8 million weighted average shares outstanding. For the three months ended March 31, 2013, the Company reported a loss of $696,797, or $0.03 per share, based on 20.2 million weighted average shares outstanding.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company reported revenues of $157,340 for the three months ended March 31, 2014, related to its grants from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development efforts. This compares to $797,040 of grant revenue reported for the same period in 2013. As of March 31, 2014, there is approximately $665,000 of unused grant funds available for use during 2014.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research and development (R&amp;D) expenses were $402,860 for the three months ended March 31, 2014, compared with $881,988 for the comparable period in 2013. R&amp;D expenses include direct costs funded by the NIH grants, as well as vaccine manufacturing costs and expenses related to the Phase 1 clinical trial of the Company&#8217;s therapeutic HIV vaccine. Costs associated with the clinical trials of GeoVax&#8217;s preventive HIV vaccine, being conducted by the HIV Vaccine Trials Network (HVTN), are being funded directly by the NIH and are therefore not reflected in GeoVax&#8217;s financial statements. General and administrative (G&amp;A) expenses were $371,802 and $612,943 for the three months ended March 31, 2014 and 2013, respectively.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA34><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA35><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax reported cash balances of $2,010,326 at March 31, 2014, as compared to $2,513,861 at December 31, 2013. Summarized financial information is attached. Further information concerning the Company&#8217;s financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA36><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA37><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About GeoVax</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA39><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax is a biotechnology company developing vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax&#8217;s unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax&#8217;s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. GeoVax has two vaccines undergoing development: GOVX-B11 and GOVX-B21. Both are for the clade B subtype of the HIV virus that is prevalent in the developed world. In both vaccines, the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GOVX-B21 differs from GOVX-B11 in co-expressing the genetic adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) with VLPs in the DNA prime. GeoVax&#8217;s vaccines are currently being tested in human clinical trials, for both preventive and therapeutic applications. Clinical trials for GeoVax&#8217;s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). GOVX-B11 has been evaluated in various doses and combinations in over 400 humans and is the company&#8217;s lead product for a preventive vaccine. GOVX-B21 has been evaluated in 40 people in a phase 1 dose escalation and regimen trial.</FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA128.1><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK128 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR128 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM128 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR128 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA128.2><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA42><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About HIV/AIDS</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">HIV can infect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be over 2 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 10&#189; minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in the Americas, Europe, and Australia. Globally, most infections involve clades AG, B, and C. GeoVax&#8217;s most advanced vaccines under development are designed to function against clade B. GeoVax has also begun early development work on vaccines for the clade C HIV subtype and its vaccines can be engineered for other subtypes as well.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA45><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA46><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">For more information, please visit&nbsp;<U>www.geovax.com</U>.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA47><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I><B>Forward-Looking Statements</B></I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA49><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA50><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management&#39;s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax&#39;s vaccines will be safe for human use, GeoVax&#39;s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax&#39;s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax&#39;s filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax&#39;s Form 10-K.</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA51><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA52><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>INVESTOR CONTACT</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA53><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Adam S. Holdsworth</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA54><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">ProActive Capital </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA55><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">646.862.4607</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA56><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">www.ProActiveCapital.com</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA58><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA57><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA60><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA59><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>FINANCIAL TABLES FOLLOW</B></FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA129.1><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK129 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR129 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM129 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR129 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA129.2><FONT style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA131><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>GEOVAX LABS, INC.</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA132><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Statements of Operations Data</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA133><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>(amounts&nbsp;in thousands, except per share data)</I></FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA134></P>
<P style="LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA130>&nbsp;</P>
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL95  border=0 cellSpacing=0 cellPadding=0>

<TR id=TBL95.finRow.1>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.1.lead.D4>&nbsp;</TD>
<TD style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.1.amt.D4 colSpan=6>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA64><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Three Months Ended</FONT></P></TD>
<TD style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.1.trail.D4>&nbsp;</TD></TR>
<TR id=TBL95.finRow.2>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.2.lead.D4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.2.amt.D4 colSpan=6>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA65><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">March 31, </FONT></P></TD>
<TD style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.2.trail.D4>&nbsp;</TD></TR>
<TR id=TBL95.finRow.3>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.lead.D3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.amt.D3 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA66><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2014</FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.trail.D3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.lead.D4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.amt.D4 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA67><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2013</FONT></P></TD>
<TD style="PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.3.trail.D4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.4>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA68><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Grant Revenue</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.symb.3>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.amt.3>157</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.lead.4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.symb.4>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.amt.4>797</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.4.trail.4 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5>
<TD style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.lead.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.symb.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.amt.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.trail.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.lead.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.symb.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.amt.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.5.trail.B4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.6>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA71><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Operating expenses:</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.lead.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.symb.B3>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.amt.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.trail.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.lead.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.symb.B4>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.amt.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL95.finRow.6.trail.B4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.7>
<TD style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 66.8%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA72><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research and development</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.amt.3>403</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.lead.4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.symb.4>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.amt.4>882</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.7.trail.4 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.8>
<TD style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA75><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">General and administrative</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.lead.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.symb.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.amt.3>371</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.lead.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.symb.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.amt.4>613</TD>
<TD style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.8.trail.4 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.9>
<TD style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.amt.3>774</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.lead.4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.symb.4>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.amt.4>1,495</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.9.trail.4 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.10>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA80><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Loss from operations</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.amt.3>(617</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.trail.3 nowrap="true">)</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.lead.4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.symb.4>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.amt.4>(698</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.10.trail.4 nowrap="true">)</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.11>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA83><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Interest income</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.lead.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.symb.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.amt.3>1</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.lead.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.symb.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.amt.4>1</TD>
<TD style="PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.11.trail.4 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.lead.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.symb.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.amt.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.trail.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.lead.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.symb.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.amt.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.12.trail.B4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.13>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA86><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Net loss</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.lead.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.symb.3>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.amt.3>(616</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.trail.3 nowrap="true">)</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.lead.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.symb.4>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.amt.4>(697</TD>
<TD style="PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.13.trail.4 nowrap="true">)</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.lead.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.symb.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.amt.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.trail.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.lead.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.symb.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.amt.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.14.trail.B4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.15>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA89><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Loss per common share</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.lead.3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.symb.3>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.amt.3>(0.02</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.trail.3 nowrap="true">)</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.lead.4>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.symb.4>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.amt.4>(0.03</TD>
<TD style="PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.15.trail.4 nowrap="true">)</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.lead.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.symb.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.amt.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.trail.B3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.lead.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.symb.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.amt.B4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL95.finRow.16.trail.B4>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL95.finRow.17>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" colSpan=2>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA92><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Weighted average shares outstanding</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.amt.3>24,765</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.trail.3 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.lead.4>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.symb.4>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.amt.4>20,166</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL95.finRow.17.trail.4 nowrap="true">&nbsp;</TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA96><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA136><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA137><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Balance&nbsp;Sheet Data</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA138><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>(amounts&nbsp;in thousands)</I></FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA135>&nbsp;</P>
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL123  border=0 cellSpacing=0 cellPadding=0>

<TR id=TBL123.finRow.1>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.lead.D2>&nbsp;</TD>
<TD style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.amt.D2 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA101><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">March 31,</FONT></P></TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.trail.D2>&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.lead.D3>&nbsp;</TD>
<TD style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.amt.D3 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA102><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dec. 31,</FONT></P></TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.1.trail.D3>&nbsp;</TD></TR>
<TR id=TBL123.finRow.2>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.lead.D2>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.amt.D2 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA103><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2014</FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.trail.D2>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.lead.D3>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.amt.D3 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA104><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2013</FONT></P></TD>
<TD style="PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id=TBL123.finRow.2.trail.D3>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL123.finRow.3>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA105><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Cash and cash equivalents</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.symb.2>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.amt.2>2,010</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.trail.2 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.symb.3>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.amt.3>2,514</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.3.trail.3 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL123.finRow.4>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA108><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Working capital</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.symb.2>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.amt.2>1,813</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.trail.2 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.amt.3>2,386</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.4.trail.3 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL123.finRow.5>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA111><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total assets</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.symb.2>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.amt.2>2,173</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.trail.2 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.amt.3>2,840</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.5.trail.3 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL123.finRow.6>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA114><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Deficit accumulated during the development stage</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.symb.2>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.amt.2>(27,668</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.trail.2 nowrap="true">)</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.amt.3>(27,052</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.6.trail.3 nowrap="true">)</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff" id=TBL123.finRow.7>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA117><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total stockholders&#8217; equity</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.symb.2>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.amt.2>1,938</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.trail.2 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.amt.3>2,527</TD>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.7.trail.3 nowrap="true">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff" id=TBL123.finRow.8>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA120><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Common shares outstanding</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.lead.2>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.symb.2>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.amt.2>24,968</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.trail.2 nowrap="true">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.lead.3>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.symb.3>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.amt.3>23,765</TD>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL123.finRow.8.trail.3 nowrap="true">&nbsp;</TD></TR></TABLE>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA124><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!$`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_***9/.E
MM"\DCK''&I9F8X"@<DD^E`#Z*^1_VGO^"X?[./[+=S<6-]XYB\6:Y;':^E^%
MH_[4F5O[K2(1`A]0\@(]*^#?CS_P=7^)-1:6'X9_"S2M(@PP6_\`$]^UU+[-
M]G@V*OT,K5ZV%R3&XC6%-V[O3\SAK9EAJ6DI:^6I^U50:CJ=MH]F]Q=W$%K!
M&,O+-($1?J3P*_G:L_\`@I!^W7^WQJ#6W@K5_'U_;L<&/P1H2V-K"">C72)E
M?JTU=EX4_P""`?[77[3]X+_XC>(;+15N/G=_%?BF?5[KG_IE$95S[%Q7H/AV
M%'_>Z\8^6[^[0Y%F\JG\"DY?A_F?LS\1/^"@_P`"_A,K_P#"1?%_X<:8\>=T
M4GB"V:4?]LU<M^E>-^,/^"^/[*/A!&_XNG;ZM(O\&EZ1?7>?HRP[?UKY)^%/
M_!IWX?T^.&3QE\7]7NFZRV^@:)#9)]!),TI/_?(KZ#^'_P#P;:?LP^#61M0T
MCQAXJ=<9.J^(9E5OJMOY0_2LG0R>G\52<_16_,M5<PGM",?5W_(Q_$/_``<Y
M_LUZ.S"T@^)&KXZ&V\/K&K?]_I8_Y5P7B'_@Z[^#FGNPL?AY\1;OT,[V%OG_
M`,CM7UOX/_X(Y?LO^!75K'X)>!I&7HU]:&_;\YV<UZ?X=_8[^$GA!5&E?"[X
M=Z=LX4VWARSB(_$1BL_;Y3'X:4WZRM^17LL>]YQ7HO\`,_->?_@[)\'S-BQ^
M"_BNY]-VN6JY_P"^5:FI_P`'55O='_1_V>O%<P_V=>4_RM37ZM:7X`T+1%`L
MM$TFT`Z""SCCQ^0K5BA2%<(JJ/11BI>-R[IAO_)V5]6QG6M_Y*C\ED_X.EV/
M)_9O\:;?4:SG_P!M*FB_X.I-'@/^F_`'QW;#N5U.)L?]]1+7ZRTV2)91AE5A
MZ$9I?7<O_P"@;_R>7^0_JV+_`.?W_DJ/RQTO_@ZU^%&X#5?AA\1].]=DEC+C
M\YEKL_#O_!T;^S3K)5;JU^(^EL>OG:+#,%_[]3N?TK]"-3\":)K2D7FC:5=@
M]1-:1R9_,5R'B']D3X4>+0PU3X8_#W4MW!^U>';.7/\`WU&:7UG+9;T9+TG_
M`)H/8XQ;5$_^W?\`@GYI_P#!:'_@L'X1^-'_``3=TJW^$VKZT8_BOK%QI,MQ
M)9SZ?<?8+'RWO0BN%<J\CPP%E^5MTJY."*]U_P""0MO\"OV#?V<-,\`ZCX]^
M&FD?%^9$N_&]O<ZS:V^IPZA*JR?8Y0[!_P#1U=(@G0%&.,LV?B/P%\.-`_X*
M1?\`!=S3_#7A/1-*T[X,_!&X?[+IVFVL<6FQV>G7!DDVQH`@6ZU.5B<#YD8G
MG%?>OQR_X-Y/V:_CQXMU?7K[1_%NEZSKM[-J%]=V/B*X9KBXF=I))"LYE7+.
MS'ICFO6Q?U.A0A@IN45+WW:S>NR>VR_$X</]8JU98F*4FO=71:;M;[L^U="\
M1Z?XHL%NM-OK/4;9_NS6LRRQM]&4D5=K\IM?_P"#7G3/!EZ][\+/CQ\0/!=V
MGS0+/`LFT]LR6SV[?C@UFR?L4_\`!2/]E0B7P-\;=)^*%A",)9ZG?K/*ZCH"
MNH1'''I/^->5_9V%J?P<0K_WDX_CJCN^N5X_Q*+^33/UKHK\BQ_P7)_:B_9`
ME2']H3]FR[?3HODDU?2X)]/1L=6\S_2+5OH)$'TKZ8_9C_X."OV;?VCY+:TN
M?%-S\/M7N2J+:^*8!:0LY[+=*SVYY]9%/M65;)<73CSJ/-'O'WE^!=/,L/)\
MK=GV>GYGVY1571M;L_$>E07VGW=M?V-T@D@N+>598IE/1E9201[@U:KRCN"B
MBB@#Y2_X*9?\%;?A_P#\$W/"\5OJ*OXG\?ZM`9M*\,V<P25TR0)[B3D009!&
MX@LQ!"JV&Q^$?[:G_!5;XU?MV7]RGC'Q7/IOAB1B8_#.BNUGI42Y)`D4'?.1
MG[TS-[`=*\M_:9^.6O\`[2W[0?C'QYXGFGEUKQ+JDUU,DK$FT3<5BMAGHL,8
M6,+V"5]A?\$`?^"<NA?MO_M"ZWXG\;VD>I>"/AHMM-+IDHS%J]_,7,$4H_BA
M18W=UZ,?+!RI8']*PN6X7*\,\365Y):OS[(^-KXROC:WL:;M%]/\SA/^">__
M``1+^+O[>=E9:Y;VL/@+X>3X9/$.KP-_IL><$V=L,-,.N')2/CASTK]>_P!D
MS_@@/^SU^S#%:WNH>'&^)/B2#:[:EXIVW42N.\=H`($&>F49A_>-?:MK:Q6-
MK'!!&D,,*A(XT4*J*!@``<``=JDKY+'\0XO$MI/ECV7ZO=_EY'OX7*:%%7:Y
MGW?^11M[?3?!7A[9$ECI.E:;"6VHJP6]K$HR3V5%`!/8"OQY_:H_X+*?&W_@
MH!^T!=?"']C_`$V_BTN(M'+XCM84^VZC&K;6NEEE'EV5IG`61OWC\$%20M?4
M?_!QE^T/?_`K_@F]JNFZ5<O:7OQ"U6W\,R2HQ5UM762:Y`(_O10M&?:4UU/_
M``0P_8ZTC]E+]@/PA?I91)XJ^(MC!XEUV\VCS9C.GF6\.>NR*%T4+TW%VZL:
M>"A2PV%>.K1YI-VBGMYM]_Z^2Q,IUJ_U6F^5)7;6_HCXAM_^#?K]K+XA1KJW
MBC]HN*VUFZ'F31OX@UB^>-CR09-R`GZ#%+<?\&\/[4V@0O>:/^TG#_:=JOG6
MF-8UF$^<O*?-O;;\P'.#CTK]5?B5^VW\'?@UXNGT#Q9\4O`'AS7+55>;3]1U
MZVM[F$,,KNC9PRY&",CD$'O6%%_P4I_9ZFE5%^-WPKW.0HSXGLQR?^VE;K.L
MS:O&.G^#3\C)Y;@D[-Z_XCTWX31:U!\*_#2>)#N\1)I5JNJG*G-V(4\[E>#^
M\W=./2N@KR?]KG]M/P!^Q/\``JX^(/C?5O*T4%([**T`GN=7G<%HX;9`0)'8
M`D<A0H+$A02/S,;_`(.-OCO\6;F]UKX8_LU7&K^#+*0JURT&HZDX5>N^:VB$
M2-Z@;L>IKS,+E>)Q2=2G'W>[:2]-3MK8VC0:A-Z_>S]BZ*^'/^"9'_!<7P/_
M`,%!/%)\$ZKHUQ\/_B5'&\D>D75P)[;5!&,R_9IMJDR)@EHG17`!(W`,1ZC_
M`,%'O^"H/P]_X)K_``^M-0\4_:=9\1ZT'_L;P]8.HN[_`&8WR,S?+%"I(#2-
MW("ACQ64\NQ,:_U9P?.^G]=/,N.+HRI>V4O=[GT5JNE6VNZ9<65Y!'<VEW&T
M,T4B[DD1A@J1Z$&OQF^$'BO7O^"1G_!=>3X=:GXA\13?"3XIND&EP:GJ<]U;
M6T%ZQ^QNOG.P#07:-;%NOEL<GFKW_$1I^T*ND?\`"9']F?\`XMUN\S[?Y.J>
M7Y/][[;Y/D]/XMFVN6_X*C?M!^`?^"P7[!5K\9_AY%>:)\1/@==QR>(M$N63
M^T+#3;ME5ID=>)H4F6*5)5X`27(4Y%?09=EF(P\W2Q,?W=3W6TT[-[/39W_,
M\G%XVE5BIT7[\-5TNNOX'[>5\V_\%:OVNO\`ABO]@[QQXOM9Q!X@N[;^Q=`Y
MPQU"ZS'$R^\8+R_2$UK?\$Q?VMH_VV?V(O`WCR26-]9N+(6&N(IYBU&W_=7&
M1VW,OF`?W9%K\W/^"]7C[5/VZO\`@HC\)_V7O"5R[+IUU"VIM'DK#?7@RTC8
M_P"?:Q#2^WG-7E9;E[GCO8UM%"[EZ1W_`,COQF+Y<-[2GO+1?,]U_P"#9;]D
M3_A3G['NI?$W4X"-;^*=X)+6209D72[8O'!SU_>2F>7W#1FOTJK\I/C[_P`%
M\-&^`/B72_@C^R_\-W^)T_A&WCT.VNU$TMDPME$7E6L-NIEN50*`9<HA(."P
M^:N,_P"(D+XO_"&^OM"^,7P1C\":U>6<LFD7;Z??0)',%)C,MI<,CS0EL*S1
M3!D#9`;&T]N+RK'XRM+$N-N;5)M7MTTWV.;#X["X>FJ*EMI>SM?U/V.HKX-_
MX)R_\%(?B[_P4G_8S\8^*/#>@_#_`,.?$SPEJ[Z=#:7R74^BZK^XCF125E6:
M`D2;2V7`*@X(.!C_`/!+[_@M/K'[4G[0GB7X-?&CPMI/PX^*.EW$L6G6=J94
MAO7AR+BT9968K<)@N,,5DCR5^[\WF3RG$15336'Q*^J\_0[8XZD^3^]L?H/-
M"ES"T<B+)'(I5E89#`]01Z5\J_M5?\$5?V=OVM(KFXU;P)9>&M>N!G^V?#.-
M+N]WJRH/*E]_,C:O/O\`@K]_P6-?_@GWJ_AGP3X"T/3/&OQ2\22),=,N3*\5
MA:LVR,ND1#O--)\D48()PS'@*&^H_P!E+4?BIKWP?TW4_B_;>$M+\7ZE$MQ/
MI/A^&86^DAAD0O++*YED7.&9=JY!`W`;BH4L5A:4<5&7*I;:ZOY=@E.A7FZ$
MES6WTT1^47CO_@FM^UG_`,$>[VY\6_L\>.]3^(/@*U8W%YH*0>9*L8Z^=II)
MCFX)S);%9>I"K7U__P`$L/\`@N#X-_X*`W$7@_Q'9P^!OBK'&Q_LII2UGK(0
M?O&LY&^;<N"6@?YU`)!<!F'W37Y"_P#!Q-_P3^T[X2:;IW[3_P`,Q_PB7BS1
M-9M3X@?3_P!RLLSR`6VI*!@+.DWEJY'^L60%N5);U,/BJ6926'Q:2J/::TUZ
M*7<XJM">#7M<.[Q6\7V\C]>J*_$W_B)*^,7_`$3./_P%>BL?]6L=V7WHU_MC
M#=W]QRW_``6__P""+GB;X.?$[Q'\8OAAI%UK_@+Q#<RZKKFEV,)DN_#=S(Q>
M:58U&7M78L^5!,19@1LP1S'_``;I_P#!0;PW^R;^T!K_`((\97]MI7ACXH_9
M5M=5F<+;V.I0EUB65^B1S+(4WG@.D><!B1_0%7Q+^V__`,$$_@9^V3=WVLVN
MFS?#GQA>[GEU;P]&D<-VYZM<6A'DRY[L`CG/+UV8;/J=;#/!8^]FK<RW\KKR
M_I'-6RN=.M]9PN_9GVT#D45^9OP.^&_[;/\`P2TLH="ALM(_:?\`A)IXV6UK
M:ZA]B\1:5`.`L'V@Y8`8Q$7E`Z*R"OJ/X+?\%4OA'\5=8AT+6]1U7X6>,W.Q
M_#7C[3Y/#^H!_P"[&9P(I^>GDR/FO$KY?./O46IQ[Q_5;KYGI4\7&6E1<K[/
M]'LSP#_@YF^#5[\2_P#@G.FMV,+S?\(+XCM-6O`O\%K(DMK(_P!%-PC'T`)K
MW+_@CM^TAI?[3/\`P3K^&>IV-Q"]]X>TB#PWJ\"'YK2\LHU@96';<JI(/595
M/>OH7QKX,T?XI>!]4T#6[*VU?0=?LY+*]M9ANBN[>5"KH?4,K'IZU^)WQ"_9
M?_:/_P""`WQYUOQI\'+>_P#'_P`&=9</=0-;R7L7D*3LBU"&/]Y%+$"52[C&
M"#\V,F.O0P2AC,)]2<DIQ=XWV=]UZG)B>;#XCZRE>+5G;IYGUS\5/^#<3X4?
MM`?&7QMX]\9^+_'TNO\`C77KS69H],NK:WMK5)9"8X5#P2,=B;5+%N2.`!@5
M\6_\%G/^"+'PM_X)Y_LJZ7XX\%ZUXUU'4[[Q';Z-+!K-W;SVYAE@N)"0$A0A
M@8EQR1@GBO<_"O\`P=F>!9-)C&O_``E\4V>IJH$R6&L6EQ#N[[6D\ML9[%:^
M;?\`@KI_P7)\#?\`!1[]F/3?`F@>$/$GAR]L?$-OK376I75J\+)%#<1E`(W9
MMQ,P(XQ\IKVLNI9S#$0C6OR)ZZJUOD>=BYY=*C)TK<WSO<L?M(:4_P"U=\?_
M`-@;X*>(KV[B\%W?P]\-RW$0E*^:;P,+@JW9VAM$A!ZC<<=:_6[]L[]M3X8_
M\$F_V<M!U'5]%N[;0!<Q:%H>A^'[.,,2(V<(BLR1HB)&Q)+#MU)K\\_VHOV`
M/%W[3?\`P38_9;^./P7EFU+XB_"WP7I2?9],D#W5Y;Q)',C6V#AKBVN%<B/J
MP>1<%@%//7/_``<%?"SXTZ%X5L/VD_@7J.O>+/`=Q)/]EA6VETV6\:)H&GDL
MKMD:-PC.!&^\*6)!R!C*OAGC%3]FN:,')2BG9WN]=>Y=*LL.Y\[M*25F]K67
MY'SQ^W__`,%$OAI^TK^V[\,_C'\&?#'B/P3XTTG4[:767O8K:+^UKB.YB-O*
MJP2/NE*F6)R<%U*#G%?3VB_#[3?V^_\`@Y:\9Z7\0XHM5\/_``V@D>PTB[^>
MWN$L8K<0Q%#PT?GW+W#+T8]002*M>%_^"]W[&7A/Q)8ZG9_LU_V-=6$Z3Q7]
MGX9T-;BS93GS8RD@;<O4;2#QQ5__`(*>?`7Q]\'?VGO"/[<W[-\3>*M'UNPM
MM2UB"RMVN1L:V6/SY(4^>2UN+;8DFWYHV3?QG*];E)-4'3=)N$HQ<G?5V:5^
MGE^!A9-.JI*?O*4DETUUL?L&;2(VGD>5'Y&SR_+VC9MQC;CIC':OQ)^(OP*\
M-?LH_P#!Q'I_@+POI\$/@3XS:6^GZ[H%O\ELMIJMK<I<VX1>%C\Z!9U7HN0`
M``!7HA_X.RO"7_"O>/A)K_\`PF?E[/L?]L6_]G>=C'^NQYNW=V\G=V]ZL_\`
M!'C]D#XJ?M7_`+;&K_M??''3KC2)KE9&\,Z?<VS6[7$DD7D)+'"_SQVL%N3'
M%O\`F=G+\XW-Y.#P>(P%.M5Q7NQ<6DK[OI;T[G?B,12Q4Z<*&K33VV74X+_@
MD%^T8/\`@E+^TW^T1\!OB3?O#H7A>"]\2Z?-,VWSWL8=[-&#QNNK(P2*.YAP
M.37@_P"S!;>,/'G[/?[7?[8NJ^9%XBFLKC0M&N@IS:WNJW$,=[+"W\)M[6>.
M)".@D;'2OH/_`(.AOV,[B/QYX"^,GA[3I+B;Q$\?@[6(H$^:>[RS:>Q]6D!E
MA_X#$.]??_P`_P"";/AWP)_P2^M/V>=;13;ZOX<EL=>N80"[W]RIDN+A3W9)
MW+(3VC0=J[:N84(48XS[55Q4O2/Q??H<T,)5E4>'^S3O;Y[?<>+_`/!MY^S%
MX5^%?_!/W1O'MA9VDOBKXASW4VHZAL!FB@@NI;>&T5NJQH(=Q4=7=B>V/HG_
M`(*=_LR^%?VI_P!B;Q_H?B>TMG.G:-=ZKIE](@\W2;R"%Y8IXW/*X90&Q]Y"
MRG@FORJ_9I_;<^+_`/P;X>,]9^$7Q>\#WOBCX<W%_)>Z1J%I)Y",7(W7%C.X
M\J2.4`,]NY5XW+<@DAM3]M'_`(+L^,_^"D_P^U'X._`#X:>*K?\`X2BVD@UF
MZRMWJ<UEM)FACC@W)`C(&#RNY^4D``G-<];*\95Q_P!:IN\&^93NK)?\!:&U
M+&X>&%]A->\E;EMK?_@GMW_!J)/]I_9.^)LA&/,\71MCTS86U9G_``<B_LA:
M!X&TKPY^TIX8UZV\&_$;1-4LK&41RF"?7G5LVTL!7G[5;[-V?XH48$_NU!H?
M\&Q/QD\)?"_]C/XSZOXA\2:)HFF:%XE2_P!0N+R\2%+*#[#"!(^XC:I*.!GJ
M5('(Q7EEC/KW_!QO_P`%+?.5M1L/V>OA;)Q@E,VI?IZ+=WQCY[Q0)_>7YMW"
M<,VJXIOEA#XGW5E[OG<RYHRP%.@E>4MOOW^1N_\`!OU\'=._;C_:Y\?_`+0O
MQ0\46?BWXC>';V.6STJ<#SH)YH\+J31X"B-$7R8%0;4*.<*52OVJK\3O^"B_
M[)?BK_@BQ^V/X?\`VCO@58,GP^U6[%IJFAPJWV73WD($MA(JYQ:7(7,;8_=3
M*,8_=@_IC^SK^W5>?M4^#]/U;PK\)/B=IL5[$DC3^*=/30[2'<.</*QEE`/1
MH8G4^M>9G=.6(<<91=Z;5ELN6WV3LRV:I)X>HK33U\[]3W]F"*23@#DD]J^3
MOVN_A?-_P4W73_A?8+-!\&[358-1\9^(.57Q"+6421Z3IY_Y:*TJ*9[D?(BI
ML0N[-Y?TVWA]O$?A\6NOQ65WYIS-!$&^SL/[A#'YU]=PP?3M57QI\2?#/PDT
MRT;7-6TO0;69A!;"XE6%6P!\J#T`QTX`KQ,/4=.?-3^+IY>?KV/3JP4X\LMN
MI4_X41X*_P"A3\._^"^+_P")HK3_`.%B>'_^@YH__@;'_P#%45'-4\RK0-FB
MBBLBPK)\:>`M#^)&AR:9XAT72=>TV;_66FHV<=U`_P!4<%3^5:U%--IW0/71
MGE6@?L;>"?`+,?!T6L^!`S[_`"/#^J3VED#_`->FXVW_`)"KN="T'6-&?;-K
MKZK#V-W:1K-C_>BV+_XY6Y15RJSE\3OZDJ$8_"K'%Z]^S?\`#SQ5J+WFI^`O
M!>HW<IR\]UHEM-(Y]V9"35+_`(9,^%?_`$3/X?\`_A.V?_QNO0:*/:U%LV')
M'L9?@_P/HOP]T5=-T#2-+T/3D9G6UT^U2VA5F.6(1`%R3U..:R?&'P+\$_$/
M4OMFO^#O"NN7F-OGZAI,%S)CTW.A->!?MU_\%(])_8I_:1^#'A/7-3\+Z'X;
M\=/JEUXBU;6#*/[,L[6!3%Y/EG'F2SR(@W`C`;CO7D?A?_@L%XD^+GC6SC\$
M:9X.U?PUXM^-%I\-_"FH%;EFU'2X[`7>IZBP#C+)G$>`J\_,#7;2P&*E%5HK
M1J]_FUO\G\M3FGBJ$7[-[K2W]>I]AK^R=\+%;(^&GP_!'0CP[:?_`!NNP\,>
M%-+\$:)#INC:;8:1IUMD0VEE;I;P19.3M1`%'))X%?$GP;_X*C>.OCE\.O@A
MI.C>'/"[?%7XH>*=8L-7LR)VT[0=&TB^G@O[\KYGF;@J0QQAFPTTV.@Q76:K
M_P`%'-<TS]F?Q9\0K31M+UJ\\3^-KGP;\(]%M]Z2>)Y%F^Q6\DK[CE)+B&ZG
M9E"A;:,-UY+J8'$WY)][;^;7Z/[F$,31MS1[=OG^J^\^E1\#/!(\3_VW_P`(
M=X6_MG?O^W_V3!]JW>OF;-V??-=57Q#X'_X*A>*_&OP*_9BU*+0O#0\:_&OQ
MF_AK7K)3,;72H+)KL:I+`-^_=&+7Y=Y(&\;LUP7@C_@JU\<?^%1^"_C9X@\&
M?#&;X(^-_&J>&;>'3KJ]B\1VMI/J4EA;7I$FZ"3+*C%%P2&XQV?]F8F6_1VW
MZW:LON?W$_7:*V]=O3_-'Z':YX<T_P`3VT4.I6%GJ$,$\=U''<P+*L<L;!XY
M`&!`=6`96'((!%7:_/W1O^"GOQ5\;_MH>(?`>CV?PBLCX<\:-X<_X0+7;ZXT
MSQ?K&E)(J/K%I/,Z6TJE"TR0HC[HU(W9Q7U5\9?VU?`'P`^(%[X<\5ZE<Z5=
MZ=X/O_'-Q.]JYM8],LI$CN'\P<>8K2)B/[QW#`K&K@:T&H-7;5[+4UAB:<TY
M+9:'I/B3PMIGC+29+#5].L-5L9?OVUY;I/$_U5@0?RJGX+^&OAWX;6DEOX=T
M#1=`@E.7CTZQBM4<^I"*`:\+UO\`X*A_#WPUKWAZTU'1?B186FO/I%N^J7/A
M6ZBT_2KG50ALK:YE8`+,_FQAE0/Y9<!RIR`ND?\`!5'X2:O\2KC01=^)+?2H
M;K4;"/Q7<:'<1^&;JZT^.22\@COROE,T2Q2Y;A"8F"LQ&*GZIB>72+MN/V]&
M_P`2N>J7O[+_`,--2GN9;CX=^!IY+U_-N'DT&U9KA]V[<Y,?S'<2<GN<UT/@
MGX=^'_AKICV7AS0M'T"SED,SV^FV4=K$[D`%BL:@$X`YZ\"OEOQ=_P`%?/`=
M]\$?&>OZ%%XG\.:CI'AZ+7]#G\6>$=0M[+6K:YN$M;6[@10LEQ`\\L0VH5D(
MD!"@'-=!I?\`P55^&\'Q3L?`M^/%5QKG_"6K\/K_`%>S\-W8T&#7]BDVOVI@
M4&YMP4;F(VG=@#-:/!XMQUB_QZ6_S(6(H)Z-'TW)$LR;74,,@X(R..13J^9_
M#W_!6SX,^(/%%S9MJ>OZ?HXMM5N]/\1WNBW$.B:\FF(TE_\`8KG;B?R4CD8X
M&&$;%"^*[C]E;]M;PM^UY!>R>'-*\9:6MK:6NI0OKFAS6$>HV=R&:"XMY&S'
M*C!&R`V]>-RKD9QGA*\(N4X-)>1I'$4I.T9*Y[!7E7[2/[,<7[0$^E7']IKI
MUQIA(`EMC<12`LK*2H=#E64'&=KC*NK`\>JT5C3J2A+FCN:2BI*TCY9_X=.^
M!O\`H.>)?^_D/_Q%%?4U%=/U_$?S,R^JTOY0HHHKC-PHHHH`****`"BBB@#Y
M+B\*6?C'_@M/J>I:DGVM_"_PCAMM.AD56B@^TZHS3.`1G>WE(N<]!C%?+7_!
M/#X9V%U\;/V6+J>2YN)7'Q$\:3>9LQ<:I=7YMGF;"C[L7RH!C'O117T]%OV,
MO\*_](J'BU/XB_Q/_P!*@1_L[^`;7]FGX(?MX?%+PW<7W_"8>'+[Q)I6B7-U
M*)$T2V5I[TQVR@+L#7,[2MR=S)'G[O/I/A_]C?P-^T%^VCX7^%/BJUU2]^'_
M`,#/A7I<OA;2+;4Y[!(+JZ;RI;R22W:.5I_+A5`P<##/\I+$T45OB9RC.I.+
MU2W_`.W8_P";^]F=&*<81:TO_P"W/_)'SU\)/AU;?#OQY)H&E7NIPZ9\)--^
M+U[X9C>82-92NR0AB[`LY1'<*2<_,22Q)J?_`((U^";O]L'6/!_@;Q[XEUW5
M?`'P!6VU3PQX9A2TM=/ENX#M@FN_+@66X:,L77=)C?R0:**]*JO]FJSZI73\
M[R_S9QPTK4XK9O\`2)1_9G\5^)/VA/\`@KEIG[/7CCQ5K?BKP5\!/$EQXG\-
MZCJ7D3Z_/<6K220175^8_-EA4R$;05+!4#,0HKZW_P""F_P"T/XW?M[?LN6&
MMO?'3=7NM7L-5LX)52'5[2$6E\MK<`J2\+3VL)901N`(/6BBN+&>YC::AI[D
MGIWY9:G1A_>P\N;7WH_FCY$\0)_PG/\`P6AU'P3K>S6;31/C'INOV^I7T27&
MJ`/`\T=@)V!*6,+QJ8X8P@X^8O71?L:>']4^-OCW]HC]EW5O%OB6#X0_"+0O
M$&EZ7I]E)!!/J,>H2REGO)1$3,\)E<Q8V@$Y<2445UR2]GZ1BUZZZ^IA%OG]
M6_T,;]DOXR>,?VX_V9_"%Q\0O$VI:CID'QA\(^"8M$MXX+;3$LM/N#<H_E+'
MDS3211^:Y8@K&H18Q7KO[.WPVLO%NF?LKPZC<7MRGBCXJ>-O&NJAG4?;M2']
MI[)'PO1/,.T#!&U>>***RQL5#FC!65WM_@D:X=N7*Y:[?^E(\#_X)_\`@*UE
M\=?M"^%=-&G:"?V=O#FKZ9X7UFPT#2_[7N2WF(+F]N);5S/,(@T7149)9`Z.
M3D?4?_!N;>Q?$7X#_$+XAK8Z?X=E\7Z_'#-X?T.`67A_3FMH`AEM+096&28N
H6E(.&95P%``HHK/./X%5^GYH,O\`XL/G^3/T7HHHKXH^D"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
